These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Increased concentrations of cholestanol and apolipoprotein B in the cerebrospinal fluid of patients with cerebrotendinous xanthomatosis. Effect of chenodeoxycholic acid. Salen G; Berginer V; Shore V; Horak I; Horak E; Tint GS; Shefer S N Engl J Med; 1987 May; 316(20):1233-8. PubMed ID: 3106810 [TBL] [Abstract][Full Text] [Related]
3. Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. Pedley TA; Emerson RG; Warner CL; Rowland LP; Salen G Ann Neurol; 1985 Oct; 18(4):517-8. PubMed ID: 4073846 [TBL] [Abstract][Full Text] [Related]
4. Long-term treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid. Berginer VM; Salen G; Shefer S N Engl J Med; 1984 Dec; 311(26):1649-52. PubMed ID: 6504105 [TBL] [Abstract][Full Text] [Related]
5. [Cerebrotendinous xanthomatosis. 2 cases with magnetic resonance imaging]. Rogelet P; Gérard JM; Michotte A; Masingue M; Destée A Rev Neurol (Paris); 1992; 148(8-9):541-5. PubMed ID: 1494725 [TBL] [Abstract][Full Text] [Related]
6. [Cerebrotendinous xanthomatosis]. Berginer VM Zh Nevropatol Psikhiatr Im S S Korsakova; 1992; 92(4):13-22. PubMed ID: 1333699 [TBL] [Abstract][Full Text] [Related]
7. Transformation of 4-cholesten-3-one and 7 alpha-hydroxy-4-cholesten-3-one into cholestanol and bile acids in cerebrotendinous xanthomatosis. Salen G; Shefer S; Tint GS Gastroenterology; 1984 Aug; 87(2):276-83. PubMed ID: 6735073 [TBL] [Abstract][Full Text] [Related]
8. [Van Bogaert's cerebrotendinous xanthomatosis. A study of 3 cases]. Laurent A; Dairou F; Luc G; Truffert J; Lapresle J; de Gennes JL Ann Med Interne (Paris); 1988; 139(6):395-402. PubMed ID: 3066249 [TBL] [Abstract][Full Text] [Related]
9. [A case of cerebrotendinous xanthomatosis with spastic paraparesis, epilepsy, and bradykinesia]. Kondo R; Wakamatsu N; Ishikawa A; Yuasa T; Miyatake T Rinsho Shinkeigaku; 1991 Jun; 31(6):677-9. PubMed ID: 1934787 [TBL] [Abstract][Full Text] [Related]
11. Biochemical abnormalities in cerebrotendinous xanthomatosis. Salen G; Shefer S; Berginer V Dev Neurosci; 1991; 13(4-5):363-70. PubMed ID: 1817043 [TBL] [Abstract][Full Text] [Related]
12. [Laboratory diagnosis of a rare congenital neurodegenerative disease: cerebrotendinous xanthomatosis]. Varga VE; Katkó M; Harangi J; Balogh I; Kapás I; Madar L; Seres I; Molnár MJ; Paragh G; Kovács GG; Harangi M Orv Hetil; 2014 May; 155(21):811-6. PubMed ID: 24836315 [TBL] [Abstract][Full Text] [Related]
13. [Timely treatment of cerebrotendinous xanthomatosis, a hereditary disorder of cholesterol metabolism]. Waterreus RJ; de Jager AE; Koopman BJ; Wolthers BG; Suurmeyer AJ Ned Tijdschr Geneeskd; 1984 Aug; 128(34):1604-7. PubMed ID: 6483031 [No Abstract] [Full Text] [Related]
14. Cerebrotendinous xanthomatosis is treatable. White SW Pediatr Dermatol; 1985 Jul; 2(4):294-6. PubMed ID: 3925446 [TBL] [Abstract][Full Text] [Related]
15. Treatment of cerebrotendinous xanthomatosis with chenodeoxycholic acid in three siblings. Chang WN; Kuriyama M; Chee EC J Formos Med Assoc; 1994 Mar; 93(3):256-9. PubMed ID: 7920069 [TBL] [Abstract][Full Text] [Related]